Medindia
Medindia LOGIN REGISTER
Advertisement

Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer

Friday, February 1, 2008 General News
Advertisement
COLUMBIA, Md., Jan. 31 Martek BiosciencesCorporation (Nasdaq: MATK), a DHA omega-3 market leader, announced today thatleading DHA researcher and expert Dr. Norman Salem, Jr., will be joiningMartek Biosciences on February 4, 2008, as vice president and chief scientificofficer.
Advertisement

Dr. Salem is one of the world's leading researchers on DHA and thefunctions of polyunsaturated fatty acids and lipids. He comes to Martek after30 years with The National Institutes of Health where he led theinternationally recognized Laboratory of Membrane Biochemistry and Biophysics.His latest scientific work focused on the role of DHA in neural development aswell as how DHA is made in the body and incorporated into the brain and otherorgans.
Advertisement

As Martek's chief scientific officer, Dr. Salem will be responsible forleading clinical research, discovery, microbial biotechnology, and analyticalsciences and will support the efforts of scientific affairs and medicalresearch.

Dr. Salem received his B.S. degree in physics from Miami University andhis Ph.D. in neurobiology from the University Of Rochester School Of Medicine.During his career, Dr. Salem has published over 200 research articles and bookchapters. He was the 2002 recipient of the Supelco/Nicholas Pelick ResearchAward from the American Oil Chemists Society, which recognizes outstandingoriginal research in fats, oils, lipid chemistry, or biochemistry. Hecurrently serves as a research professor in the Department of Pediatrics atthe F. Edward Hebert School of Medicine of Uniformed Services University ofthe Health Sciences.

"We are pleased to welcome Dr. Salem, a prominent expert on the science ofDHA, to Martek. His scientific knowledge and experience in DHA research willprovide Martek with important senior-level leadership for our clinical,scientific and research areas," said Steve Dubin, CEO of Martek Biosciences.

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in theinnovation and development of DHA omega-3 products that promote health andwellness through every stage of life. The company produces life'sDHA(TM), asustainable and vegetarian source of the omega-3 fatty acid DHA(docosahexaenoic acid), for use in foods, beverages, infant formula, andsupplements. The company also produces life'sARA(TM) (arachidonic acid), anomega-6 fatty acid, from a sustainable, vegetarian source, for use in infantformula. For more information on Martek Biosciences Corporation, visitwww.martek.com. For a complete listing of life'sDHA products, visitwww.lifesdha.com.

Sections of this release contain forward-looking statements. Thesestatements are based upon numerous assumptions which Martek cannot control andinvolve risks and uncertainties that could cause actual results to differ.These statements should be understood in light of the risk factors set forthin the company's filings with the Securities and Exchange Commission,including, but not limited to, the company's Form 10-K for the fiscal yearended October 31, 2007 and other filed reports on Form 10-K, Form 10-K/A, Form10-Q and Form 8-K.Contact: Cassie France-Kelly Consumer and Trade Media Martek Biosciences (443) 542-2116 [email protected] Kyle Stults Investor Relations Martek Biosciences (410) 740-0081 [email protected]

SOURCE Martek Biosciences Corporation
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close